An updated panel of 578 barcoded cancer cell lines were used to profile the activity of 4518 existing drugs with a diversity of indications. An unexpectedly large number of non-oncology drugs selectively inhibited subsets of cancer cell lines. Results were used to begin the PRISM drug repurposing resource (depmap.org/repurposing).
Menu
PRISM will be accepting submissions for our next screen May 27 – June 13!
DMSO-soluble small molecules (single agent and combination format) and single agent antibodies, ADCs, and growth-inhibiting cytokines will be accepted for our 930 cancer cell line screen.
